Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

The OncFive: Top Oncology Updates for the Week of 6/8

June 14th 2025

The FDA has approved new options in head and neck cancer, lung cancer, and bladder cancer—and more from OncLive this week.

Dr Sonpavde on Nivolumab Plus Ipilimumab in Untreated Unresectable/Metastatic Urothelial Carcinoma

June 12th 2025

Guru P. Sonpavde, MD, discusses nivolumab plus ipilimumab in treatment-naive unresectable or metastatic urothelial carcinoma.

Dr Hayne on Mitomycin/BCG as an Alternative to BCG Alone in Non–Muscle-Invasive Bladder Cancer

June 12th 2025

Dickon Hayne, MD, FRCS, MBBS, discusses the use of mitomycin plus BCG as a potential alternative to BCG alone in non–muscle-invasive bladder cancer.

Dr Huang on the FDA Approval of Mitomycin Intravesical Solution for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

William C. Huang, MD, details the FDA approval of intravesical mitomycin for recurrent, low-grade, intermediate-risk non–muscle invasive bladder cancer.

FDA Approves Intravesical Mitomycin for Recurrent, Low-Grade, Intermediate-Risk NMIBC

June 12th 2025

The FDA approved mitomycin intravesical solution for recurrnet, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

EV-302 Regimen Shows Sustained Efficacy Vs Chemo Across Key Subgroups of Urothelial Cancer

June 10th 2025

First-line enfortumab vedotin plus pembrolizumab continued to demonstrate efficacy across subgroups of locally advanced or metastatic urothelial carcinoma.

ABLE-32 Looks to Expand the Use of Nadofaragene Firadenovec Into Intermediate-Risk NMIBC

June 10th 2025

A deep dive into the phase 3b ABLE-32 trial reveals the need for more treatments for patients with intermediate-risk NMIBC.

UGN-102 Elicits Nearly 80% CR Rate in Recurrent Low-Grade NMIBC

June 9th 2025

UGN-102 showed strong responses in patients with recurrent, intermediate-risk, low-grade non–muscle-invasive bladder cancer, per the phase 3 ENVISION trial.

Dr Schmidt on the Role of Minimally Invasive and Robotic Modalities in Bladder Cancer

June 9th 2025

Bogdana Schmidt, MD, MPH, discusses the role of minimally invasive and robotic strategies for the treatment of patients with bladder cancer.

Padeliporfin VTP Shows Safety, Clinical Activity in Upper Tract Urothelial Cancer

June 7th 2025

The photosensitizing drug and light delivery system yielded complete responses and a low rate of disease recurrence in patients with low-grade UTUC.

Perioperative Sacituzumab Govitecan Plus Pembrolizumab Is Safe, Active in MIBC

June 6th 2025

Perioperative sacituzumab govitecan-hziy plus pembrolizumab was safe and active in muscle-invasive bladder cancer.

Mitomycin/BCG Combo Could Alleviate BCG Shortage Concerns for NMIBC

June 1st 2025

BCG plus mitomycin may represent good alternative to BCG alone in NMIBC.

First-Line Nivolumab Plus Ipilimumab Does Not Boost OS in Cisplatin-Ineligible Unresectable Urothelial Carcinoma

June 1st 2025

Nivolumab plus ipilimumab failed to improve overall survival in cisplatin-ineligible, unresectable urothelial carcinoma.

Sasanlimab Plus BCG Displays EFS Benefit Across Key Subgroups in High-Risk Non–Muscle Invasive Bladder Cancer

May 31st 2025

Sasanlimab plus BCG led to a PFS benefit vs BCG alone in patients with CIS and T1 high-risk non–muscle invasive bladder cancer.

Revisit Every OncLive On Air Episode From May 2025

May 30th 2025

Read a recap of the episodes of OncLive On Air that debuted in May 2025.

FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

May 28th 2025

Dr Galsky discusses the FDA approval of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab monotherapy for MIBC.

CHMP Recommends EU Approval of Perioperative Durvalumab for Muscle-Invasive Bladder Cancer

May 27th 2025

CHMP backed perioperative durvalumab plus neoadjuvant chemotherapy for MIBC based on the NIAGARA trial, which showed improved EFS vs chemotherapy alone.

The OncFive: Top Oncology Articles for the Week of 5/18

May 24th 2025

FDA’s ODAC voted on therapeutic approaches in lymphoma, bladder, prostate, and myeloma, and more from OncLive this week.

FDA’s ODAC Votes Against Risk/Benefit Profile of UGN-102 in Recurrent, Low-Grade, Intermediate-Risk NMIBC

May 21st 2025

The FDA’s ODAC voted against the risk/benefit profile of UGN-102 for recurrent, low-grade, intermediate-risk non–muscle-invasive bladder cancer.

The ‘Bar Is High’ to Usurp BCG, but Novel Therapies Could Drive Change in Bladder Cancer Management

May 20th 2025

Bogdana Schmidt, MD, MPH, discussed FDA-approved BCG-refractory treatments and recent shifts in BCG-naive NMIBC management.